<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00911729</url>
  </required_header>
  <id_info>
    <org_study_id>A1970</org_study_id>
    <nct_id>NCT00911729</nct_id>
  </id_info>
  <brief_title>Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma</brief_title>
  <official_title>Content Validation of the EORTC QLQ-C30 Version 3.0, and NIH Quality of Life and Symptoms Questionnaire for Pheochromocytoma and Paraganglioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molecular Insight Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molecular Insight Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this qualitative study is to evaluate the clarity and comprehensiveness of two
      disease-specific questionnaires, and to evaluate how effective these questionnaires are at
      assessing the quality of life and symptoms of patients with pheochromocytoma or
      paraganglioma.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2009</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The main objective of this study is to evaluate content validity of the NIH Quality of Life and Symptoms Questionnaire for Pheochromocytoma and Paraganglioma and EORTC-QLQ-C30 in patients with pheochromocytoma or paraganglioma.</measure>
    <time_frame>Single Visit</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pheochromocytoma</condition>
  <condition>Paraganglioma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a documented (medical record) diagnosis of either pheochromocytoma or
        paraganglioma with active symptoms or who are within 60 days of curative therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent and be willing to comply with protocol requirements

          -  Participant is aged â‰¥ 18

          -  Have a documented (medical record) diagnosis of either pheochromocytoma or
             paraganglioma with active symptoms or within 60 days of curative therapy

        Exclusion Criteria:

        Patient is currently asymptomatic from pheochromocytoma/paraganglioma diagnosis or duration
        &gt; 60 days from curative therapy

          -  Participant has a clinically significant disorder, including alcohol or drug abuse,
             which may interfere with study participation or which may affect the outcome of the
             study as judged by the investigator.

          -  Participant has a mental disability or significant mental illness, legal incapacity or
             limited legal capacity or any other lack of fitness, in the investigator's opinion, to
             preclude the subject's participation in or ability to complete the study.

          -  Participant is currently too unwell to take part in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emuella M Flood, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford Outcomes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oxford Outcomes- Nationwide Recruitment within the US</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2009</study_first_posted>
  <last_update_submitted>June 7, 2013</last_update_submitted>
  <last_update_submitted_qc>June 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2013</last_update_posted>
  <responsible_party>
    <name_title>Meredith Frank-Molnia</name_title>
    <organization>Molecular Insight Pharmaceuticals, Inc</organization>
  </responsible_party>
  <keyword>paraganglioma</keyword>
  <keyword>pheochromocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pheochromocytoma</mesh_term>
    <mesh_term>Paraganglioma</mesh_term>
    <mesh_term>Carotid Body Tumor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

